Antares Pharma Inc., of Ewing, N.J., said the FDA issued a complete response letter (CRL) on the new drug application for the company's Xyosted (testosterone enanthate) injection. The CRL lists two possible problems with the drug's clinical data from studies QST-13-003 and QST-15-005.